Features

Viewpoints

On-Body Injections of Pegfilgrastim May Not Always Be Preferred — But They’re On Schedule

By

Julia Faith Sklar

Publish Date November 4, 2020

Preferences are tied not just to the experience of receiving an injection, but also to factors related to a patient’s access to different types of care settings.

American Cancer Society Updates Cervical Cancer Screening Guidelines

By

Victoria Forster, PhD

Publish Date September 16, 2020

New guidelines from the American Cancer Society (ACS) appear to move away from the reliance on cytology screening via Pap testing.

From the Advisory Board

We Can Treat Hodgkin’s Lymphoma Like Melanoma?

By

Isabel Cunningham, MD

Publish Date September 3, 2015

Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.

Slideshows

BAVENCIO (avelumab) for Merkel Cell Carcinoma

IMLYGIC (talimogene laherparepvec) for Melanoma

Features

First GnRH Receptor Antagonist Enters Advanced Prostate Cancer Treatment Portfolio

By

Rachel Narozniak, MA

Publish Date January 20, 2021

Daniel J. George, MD, a lead investigator on the HERO study, discusses the implications of relugolix’s approval for advanced prostate cancer.

Oral Contraceptives Found to Protect Against Ovarian and Endometrial Cancer for up to 35 Years After Discontinuation

By

Julia Faith Sklar

Publish Date January 19, 2021

Investigators of the observational study sought to clarify the time-dependent effects between long-term oral contraceptive use and risk for breast, ovarian, and endometrial cancer risk.

What to Expect: Enrolling on a Cancer Clinical Trial During COVID-19

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date January 14, 2021

This fact sheet reviews potential adaptations made to clinical trials that patients may encounter during the COVID-19 pandemic.